Hester Biosciences is currently trading at Rs. 1725.00, up by 14.50 points or 0.85% from its previous closing of Rs. 1710.50 on the BSE.
The scrip opened at Rs. 1742.00 and has touched a high and low of Rs. 1750.00 and Rs. 1680.00 respectively. So far 1409 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 2044.40 on 24-Sep-2019 and a 52 week low of Rs. 870.00 on 23-Mar-2020.
Last one week high and low of the scrip stood at Rs. 1825.00 and Rs. 1618.10 respectively. The current market cap of the company is Rs. 1451.78 crore.
The promoters holding in the company stood at 53.73%, while Institutions and Non-Institutions held 0.78% and 45.48% respectively.
Hester Biosciences has signed the agreement towards receiving the indigenously developed technology from ICAR-IVRI (Indian Council of Agriculture Research - Indian Veterinary Research Institute), for developing the Brucella Abortus S19 Delta Per vaccine.
While Hester is currently manufacturing the conventional Brucella Abortus S19 vaccine and supplying to all the states in India, the S19 Delta Per new generation vaccine technology developed by IVRI will be a step forward towards developing a Brucella vaccine with enhanced safety, immunogenicity, as well as assuring lifelong immunity with a single shot in calf-hood.
The Government of India has planned to immunize 4 crore female calves in India in the first phase against Brucella through vaccination. Hester has been and commits to remain a part of the Government of India’s immunization program against Brucella in cattle.
With this vaccine Hester hopes to reach new heights not only within India but also become a channel for immunizing cattle against Brucella, worldwide. Hester hopes to launch the Brucella Abortus S19 Delta Per vaccine in 18 months.
Hester Biosciences is engaged in the manufacturing of poultry vaccines.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1624.95 |
| Dr. Reddys Lab | 1315.35 |
| Cipla | 1286.75 |
| Zydus Lifesciences | 929.95 |
| Lupin | 2272.60 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: